Mitosek-Szewczyk K, Gordon-Krajcer W, Walendzik P, Stelmasiak Z. Original articleFree radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathologica. 2010;48(2):116-122.
APA
Mitosek-Szewczyk, K., Gordon-Krajcer, W., Walendzik, P., & Stelmasiak, Z. (2010). Original articleFree radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathologica, 48(2), 116-122.
Chicago
Mitosek-Szewczyk, Krystyna, Wanda Gordon-Krajcer, Piotr Walendzik, and Zbigniew Stelmasiak. 2010. "Original articleFree radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy". Folia Neuropathologica 48 (2): 116-122.
Harvard
Mitosek-Szewczyk, K., Gordon-Krajcer, W., Walendzik, P., and Stelmasiak, Z. (2010). Original articleFree radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathologica, 48(2), pp.116-122.
MLA
Mitosek-Szewczyk, Krystyna et al. "Original articleFree radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy." Folia Neuropathologica, vol. 48, no. 2, 2010, pp. 116-122.
Vancouver
Mitosek-Szewczyk K, Gordon-Krajcer W, Walendzik P, Stelmasiak Z. Original articleFree radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathologica. 2010;48(2):116-122.
Multiple sclerosis (MS) patients were found to have elevated thiobarbituric acid reactive material levels, increased soluble sulfhydryl groups and reduced protein sulfhydryl groups in cerebrospinal fluid and serum, and slightly reduced superoxide dismutase in serum, which suggested disease activating free radical peroxidation. Moreover, levels of these varied across methylprednisolone (MP) therapy. We observed significant differences in the levels of peroxidation products between MS patients and controls. These changes were most evident in relapse. After MP therapy, levels of these indicators approached control values, especially in the remission period. Our findings suggest that MP protects against free radical attack.